Grasil 500mg Injection (Amikacin Sulphate)

Drug Class: Aminoglycoside Antibiotic | Form: Intramuscular (IM) / Intravenous (IV) Injection | Prescription Status: Prescription Only (Rx) — DRAP Registered

What is Grasil 500mg Injection?

Grasil 500mg Injection contains Amikacin Sulphate — delivering the highest available single-vial dose of Amikacin at 500mg — reserved for adults and larger patients where once-daily high-dose aminoglycoside therapy is prescribed, or where the required weight-based dose is most efficiently and accurately delivered from a single 500mg vial rather than multiple smaller vials.

At this strength, Grasil 500mg is used in the most serious clinical scenarios — severe systemic infections, ICU-level sepsis, ventilator-associated pneumonia, and life-threatening infections caused by multi-drug resistant (MDR) Gram-negative organisms — where achieving the highest possible peak Amikacin concentration relative to the infecting organism's Minimum Inhibitory Concentration (MIC) is critical for treatment success. The concentration-dependent killing mechanism of aminoglycosides means that a single high-peak dose kills bacteria more rapidly and completely than the same total amount divided into smaller multiple doses.

Grasil 500mg is strictly a hospital and intensive care setting medicine. At this dose, the risks of nephrotoxicity and irreversible ototoxicity are at their highest within the Grasil range — making mandatory therapeutic drug monitoring, precise kidney function assessment, and continuous clinical surveillance more critical here than at any lower strength. It must be prepared and administered exclusively by qualified healthcare professionals under specialist medical supervision.

What is Grasil 500mg Injection Used For?

Grasil 500mg Injection is approved for short-term treatment of the following severe systemic bacterial infections caused by susceptible organisms:

• Lung infections — severe hospital-acquired pneumonia, ventilator-associated pneumonia, and lower respiratory tract infections caused by MDR Gram-negative organisms including resistant Pseudomonas aeruginosa (پھیپھڑوں کا انتہائی شدید انفیکشن)
• Blood infections (septicaemia) — life-threatening Gram-negative bacteraemia and septic shock requiring immediate maximum-concentration antibiotic coverage (خون کا انتہائی شدید بیکٹیریل انفیکشن)
• Abdominal infections — severe peritonitis and intra-abdominal sepsis, typically combined with anaerobic coverage such as Metronidazole
• Skin and soft tissue infections — necrotising infections and serious wound infections involving MDR Gram-negative organisms (جلد کا شدید انفیکشن)
• Urinary tract infections — complicated pyelonephritis and urosepsis caused by organisms resistant to all other available antibiotic options (گردے کا شدید انفیکشن)
• Burns infections — life-threatening bacterial superinfection of extensive burns — Pseudomonas coverage is particularly critical in burns patients
• MDR Gram-negative infections — infections caused by extensively drug-resistant Pseudomonas, Acinetobacter baumannii, Klebsiella pneumoniae, and Enterobacter species confirmed susceptible to Amikacin on culture and sensitivity testing

How Does Grasil 500mg Injection Work?

Amikacin kills bacteria by permanently disrupting bacterial protein synthesis — the fundamental process bacteria depend on to produce the proteins essential for their structural integrity, cellular function, and reproduction.

Once inside the bacterial cell, Amikacin binds irreversibly to the 30S ribosomal subunit — the molecular machinery responsible for assembling proteins. This permanent binding corrupts the entire protein production process, causing bacteria to manufacture fatally defective proteins. Without functioning proteins, bacteria cannot maintain their cell membrane, sustain internal processes, or replicate — leading to rapid and complete bacterial death.

Amikacin is bactericidal — it actively kills bacteria rather than merely suppressing growth — a critical advantage in life-threatening systemic infections where speed and completeness of bacterial eradication directly determines survival outcomes.

The pharmacodynamic advantage of the 500mg dose:

Aminoglycosides are concentration-dependent antibiotics — meaning their bacterial killing ability is directly proportional to how high the peak blood concentration rises relative to the MIC of the infecting organism. At 500mg, Grasil achieves the highest peak plasma concentrations within the range — maximising the concentration-to-MIC ratio and producing the fastest and most complete bacterial eradication achievable with Amikacin. This is particularly important in ICU patients with septic shock where rapid bacterial load reduction is essential for survival.

Dosage and Administration

⚠️ Grasil 500mg is strictly an ICU and hospital specialist medicine. All doses must be individually calculated based on actual body weight and kidney function. Therapeutic drug monitoring is mandatory. Prepare and administer exclusively under qualified specialist medical supervision.

Administration Guidelines:

• Administer IV doses as a slow infusion over 30 to 60 minutes — rapid IV bolus is absolutely prohibited at this dose and carries a high risk of acute toxicity
• For IM administration in appropriate patients, inject deep into a large muscle with strict site rotation — note that the 500mg volume may require splitting across two injection sites
• Therapeutic drug monitoring is mandatory — peak levels 30 minutes after infusion completion and trough levels immediately before the next dose must be measured and verified before continuing treatment
• Assess and document kidney function before the first dose — repeat serum creatinine and urine output assessment every 2 to 3 days throughout treatment
• Maintain full patient hydration throughout — dehydration at 500mg doses dramatically escalates nephrotoxicity risk
• Maximum duration: 10 days — beyond this, the cumulative risk of permanent hearing loss and kidney damage becomes clinically unacceptable

Active Ingredient

Who Should NOT Receive Grasil 500mg Injection?

Do not administer if the patient:

• Is allergic to Amikacin or any other aminoglycoside antibiotic
• Has a history of aminoglycoside-induced hearing loss, tinnitus, or severe kidney damage
• Has myasthenia gravis — aminoglycosides cause severe, potentially fatal worsening of neuromuscular blockade

Always inform the treating doctor before administration if the patient has:

• Any degree of kidney impairment — at 500mg, accumulation in kidney-impaired patients is rapid and dangerous; significant dose reduction and interval extension are mandatory from the first dose
• Pre-existing hearing loss or tinnitus — existing cochlear damage makes irreversible ototoxicity at 500mg substantially more likely and more severe
• Dehydration or haemodynamic instability — correct fluid and blood pressure status before the first dose; the 500mg dose in a dehydrated patient carries extremely high acute nephrotoxicity risk
• Neuromuscular disorders — Parkinson's disease, botulism, or any condition affecting neuromuscular transmission
• Is pregnant — Amikacin causes permanent congenital deafness; at 500mg this risk is highest; use only when no safer alternative exists for an immediately life-threatening infection
• Is elderly — even mildly reduced kidney function in elderly patients causes disproportionate Amikacin accumulation at this dose

Side Effects

At 500mg — the highest Grasil formulation — the risks of Amikacin's two most serious toxicities are at their peak. Close, proactive monitoring is not optional at this dose — it is a clinical necessity.

Common Side Effects:

• Injection site pain, redness, or swelling
• Mild nausea or vomiting
• Headache or dizziness

The Two Critical Toxicities:

🔴 Nephrotoxicity (Kidney Damage) — Amikacin accumulates in kidney proximal tubule cells causing direct and progressive cellular injury — presenting as rising serum creatinine, falling urine output, and electrolyte disturbances. At 500mg, this accumulation is faster and more pronounced than at any lower dose. Kidney function tests before starting and every 2 to 3 days throughout are mandatory. Early detection allows dose modification and usually reversible recovery — delayed detection risks progression to acute kidney failure.

🔴 Ototoxicity (Permanent Hearing and Balance Damage) — Amikacin concentrates in cochlear fluid (کان کا اندرونی حصہ) and destroys cochlear hair cells irreversibly — causing permanent high-frequency hearing loss (بہرا پن) that frequently becomes apparent only after treatment ends. At 500mg, cochlear exposure is at its highest within the Grasil range. There is no treatment that can restore Amikacin-induced hearing loss — it is permanent. Vestibular damage causing lasting dizziness and imbalance can also occur. Any ringing in the ears, hearing reduction, or new dizziness must be reported to the medical team immediately — never wait for the next scheduled review.

Other Serious Side Effects:

• Neuromuscular blockade — potentially fatal respiratory muscle paralysis in susceptible patients or those receiving neuromuscular blocking agents
• Severe allergic reaction — sudden rash, facial or throat swelling, difficulty breathing — emergency treatment required immediately (یہ طبی ہنگامی صورتحال ہے)
• Electrolyte disturbances — hypokalaemia, hypomagnesaemia, and hypocalcaemia from tubular damage requiring close monitoring and active replacement therapy

Drug Interactions

Storage Instructions

• Store below 25°C in a cool, dry place protected from direct light
• Do not freeze — freezing damages solution integrity and alters effective concentration
• Keep in original packaging until immediately before use
• Keep out of reach of children (بچوں کی پہنچ سے دور رکھیں)
• Inspect every vial before use — solution must be clear and colourless to pale yellow; discard immediately if cloudy, discoloured, or particulate matter is present
• Use immediately once opened — never store a partially used vial for a subsequent dose
• Do not use after the expiry date on the vial or outer carton

Frequently Asked Questions

Why is Grasil 500mg specifically used in ICU settings for the most severe infections?

 Critically ill patients in the ICU — particularly those with septic shock, ventilator-associated pneumonia, or MDR Gram-negative bacteraemia — present unique pharmacokinetic challenges. Severe illness causes significant changes in how the body distributes and eliminates medicines, often requiring higher doses to achieve the same therapeutic blood levels that lower doses achieve in healthier patients. The 500mg vial allows delivery of the full once-daily high-dose regimen required to achieve peak concentrations sufficiently above the MIC of resistant organisms to ensure effective bacterial killing. In ICU patients, sub-therapeutic dosing of Amikacin can result in treatment failure with a directly fatal outcome — making adequate dosing at the 500mg level, guided by TDM, clinically critical.

Is once-daily dosing with Grasil 500mg safer than twice-daily lower doses?

Once-daily high-dose Amikacin is not inherently safer — but it exploits Amikacin's pharmacodynamics more effectively while potentially reducing the accumulation pattern associated with multiple daily doses. Aminoglycosides exhibit saturable uptake in kidney and cochlear tissue — meaning that once these tissues are fully saturated after a dose, additional drug in the bloodstream is not taken up further. By allowing trough levels to fall very low — essentially to zero — before the next once-daily dose, kidney and cochlear tissue have a daily washout period that reduces progressive accumulation compared to maintaining constantly elevated levels with multiple daily doses. However, once-daily dosing at 500mg still carries substantial toxicity risk, and TDM remains mandatory regardless of dosing strategy.

What monitoring is specifically required when using Grasil 500mg?

 At the 500mg dose, monitoring requirements are more intensive than at lower Amikacin strengths. Before the first dose: measure serum creatinine, calculate creatinine clearance, document baseline hearing status, and confirm adequate hydration. During treatment: measure serum creatinine and urine output every 2 to 3 days — or daily in ICU patients; perform TDM with peak levels after the first dose and then every 2 to 3 days; measure serum potassium, magnesium, and calcium at least every 3 days; actively ask the patient about tinnitus, hearing changes, or new dizziness at every clinical review. Any deterioration in kidney function or any auditory symptom requires immediate medical review and likely treatment modification.

Can the 500mg vial be split across two patients to reduce waste?

 No — under no circumstances should a single Amikacin vial be split between two patients. Once opened, the vial is considered used and must be discarded — regardless of remaining volume. Splitting vials introduces serious risks: contamination of the sterile solution, inaccurate dose measurement, potential bacterial growth in a partially used vial stored between administrations, and the risk of cross-patient infection transmission. Each patient must receive a freshly opened vial for each dose, even if the entire contents are not required. Clinical pharmacy departments have protocols for managing leftover volumes from opened vials — these must always be followed.

How should the 500mg dose be adjusted in patients who develop rising creatinine during treatment?

A rising serum creatinine during Amikacin treatment is a direct signal of developing nephrotoxicity and requires immediate clinical action — not observation until the next scheduled test. The medical team will first confirm adequate hydration and review all concurrent nephrotoxic medicines for possible discontinuation. The Amikacin dose will then be adjusted — either by reducing the individual dose, extending the interval between doses, or both — based on the degree of creatinine rise and the calculated new creatinine clearance. TDM results will be reviewed to confirm current drug levels and guide the adjustment. If creatinine continues to rise despite dose adjustment, discontinuation of Amikacin and substitution with a less nephrotoxic antibiotic will be considered, balancing the infection treatment need against ongoing kidney damage risk.

Is Grasil 500mg ever used outside hospital settings?

No — Grasil 500mg Injection is exclusively a hospital and clinical setting medicine and should never be used outside this environment under any circumstances. The requirement for intravenous administration with careful 30 to 60-minute infusion control, the mandatory therapeutic drug monitoring that requires a clinical laboratory, the need for twice or thrice-weekly kidney function testing, the clinical expertise required to recognise and manage nephrotoxicity and ototoxicity, and the need for emergency response capability in case of severe allergic reaction or neuromuscular blockade — all make home or outpatient administration of 500mg Amikacin unsafe and clinically inappropriate.

---

⚕️ Medical Disclaimer: This product description is provided for general informational purposes only and does not replace professional medical advice, diagnosis, or treatment. Grasil 500mg Injection is a prescription-only hospital medicine requiring mandatory therapeutic drug monitoring and continuous kidney function surveillance throughout treatment. It must be administered exclusively by qualified healthcare professionals under specialist supervision. Report any hearing changes, tinnitus, reduced urination, or muscle weakness to the medical team immediately.

---

DRAP Registered | Prescription Required (Rx) | ICU and hospital specialist use only — mandatory TDM and kidney monitoring — report hearing changes or reduced urination immediately — maximum 10 days treatment